SRR8613779
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- ANGIOGENESIS+0.520
- TGF_BETA_SIGNALING+0.460
- UV_RESPONSE_DN+0.450
- HYPOXIA+0.420
- MYOGENESIS+0.400
- APICAL_JUNCTION+0.350
- NOTCH_SIGNALING+0.350
- HEDGEHOG_SIGNALING+0.320
- COAGULATION+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- MYC_TARGETS_V2-0.570
- INTERFERON_GAMMA_RESPONSE-0.500
- MYC_TARGETS_V1-0.460
- OXIDATIVE_PHOSPHORYLATION-0.410
- ALLOGRAFT_REJECTION-0.370
- DNA_REPAIR-0.320
- FATTY_ACID_METABOLISM-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- MTORC1_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613703 | — | D | 0.907 |
| 2 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.904 |
| 3 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.894 |
| 4 | TCGA-P3-A6T8-01A-11R-A34R-07 | — | — | 0.887 |
| 5 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.871 |
| 6 | ee3e7969-ff2a-4b27-8f15-6cb46eed7c61 | — | — | 0.866 |
| 7 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.858 |
| 8 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.849 |
| 9 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.849 |
| 10 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |